Boston Scientific (BSX) Cash from Financing Activities (2009 - 2026)

Boston Scientific (BSX) has 18 years of Cash from Financing Activities data on file, last reported at -$260.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 211.59% year-over-year to -$260.0 million; the trailing twelve-month figure through Mar 2026 stood at -$888.0 million (down 285.77% YoY), and the FY2025 full-year result was -$395.0 million, down 121.78% from the prior year.
• Cash from Financing Activities slipped to -$260.0 million in Q1 2026, from -$184.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.6 billion in Q1 2024 to a low of -$344.0 million in Q2 2022.
• A 5-year average of $36.2 million and a median of $1.0 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 17300.0% in 2022 and soared 2373.91% in 2024, its largest moves.
• Tracing BSX's Cash from Financing Activities over 5 years: stood at $1.0 million in 2022, then surged by 1400.0% to $15.0 million in 2023, then jumped by 1326.67% to $214.0 million in 2024, then sank by 185.98% to -$184.0 million in 2025, then slumped by 41.3% to -$260.0 million in 2026.
• Business Quant data shows BSX's Cash from Financing Activities at -$260.0 million in Q1 2026, -$184.0 million in Q4 2025, and -$104.0 million in Q3 2025.